Savient Pharmaceuticals, Inc. Announces Appellate Court Decision In Patent Infringement Lawsuit Against Sandoz Pharmaceuticals And Upsher-Smith Laboratories

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announced today that the United States Court of Appeals for the Federal Circuit in Washington, D.C. (the “Federal Circuit”) has issued late today an Order temporarily enjoining all sales of generic oxandrolone tablets by Sandoz Pharmaceuticals, a Novartis Pharmaceuticals company (NYSE:NVS), and Upsher-Smith Laboratories until the Federal Circuit has the opportunity to review this matter. This Order was issued by the Federal Circuit as a result of an appeal filed today by Savient of the Order late last Friday of the U.S. District Court for the District of New Jersey which would have lifted at 5:00 p.m. today a separate Temporary Restraining Order (“TRO”) issued by that Court on December 4, 2006.